S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
The single greatest medical breakthrough of all time? (Ad)
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
LON:STX

Shield Therapeutics (STX) Share Forecast, Price & News

GBX 11.25
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
11.03
11.70
50-Day Range
6.40
11.55
52-Week Range
5.80
12.50
Volume
1.46 million shs
Average Volume
2.45 million shs
Market Capitalization
£80.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

STX stock logo

About Shield Therapeutics (LON:STX) Stock

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

STX Price History

STX Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Elon Did It Again: This Could be Bigger than Tesla
Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.
Swiss Want In On Germany's Sky Shield Plan
Shield Therapeutics ready to go full throttle in the US
Proactive research analyst on Shield Therapeutics
Shield Therapeutics completes fundraise
See More Headlines
Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

Net Income
£-40,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£4.47 million
Cash Flow
GBX 1.77 per share
Book Value
GBX 2 per share

Miscellaneous

Free Float
N/A
Market Cap
£80.22 million
Optionable
Optionable
Beta
1.17
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Gregory P. Madison (Age 55)
    CEO & Exec. Director
    Comp: $678k
  • Dr. Christian Schweiger M.D. (Age 56)
    Ph.D., Co-Founder & Non Exec. Director
    Comp: $45k
  • Mr. Hans-Peter Rudolf
    Chief Financial Officer
  • Ms. Lucy Kate Huntington-Bailey
    Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood
    Group HR Director
  • Ms. Carol Akinola
    Head of Pharmacovigilance & Medical Information
  • Mr. Andrew Hurley (Age 54)
    Chief Commercial Officer
  • Kate Armanetti
    Sr. Director of People & Culture













STX Stock - Frequently Asked Questions

Should I buy or sell Shield Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" STX shares.
View STX analyst ratings
or view top-rated stocks.

How have STX shares performed in 2023?

Shield Therapeutics' stock was trading at GBX 7.05 at the beginning of 2023. Since then, STX stock has increased by 59.6% and is now trading at GBX 11.25.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 11.25.

How much money does Shield Therapeutics make?

Shield Therapeutics (LON:STX) has a market capitalization of £80.22 million and generates £4.47 million in revenue each year. The company earns £-40,440,000.00 in net income (profit) each year or GBX (0.16) on an earnings per share basis.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The official website for the company is www.shieldtherapeutics.com. The company can be reached via phone at +44-191-5118500.

This page (LON:STX) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -